ArticleCureus2026
CAPRIN1 (Cell Cycle-Associated Protein 1)-Related Neurodevelopmental Disorder: A Novel Mutation With Ataxia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the cell cycle-associated protein 1 (CAPRIN1) gene have been shown to present with language impairment, speech delay, intellectual disability, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), respiratory problems, limb and skeletal anomalies, developmental delay, feeding difficulties, seizures, ophthalmologic problems, cerebellar ataxia, dysmorphic features, and hearing loss. CAPRIN1 is involved in regulating the transport and translation of neuronal mRNAs, which encode for cell proliferation and migration proteins, and has been identified as a core component of stress granules. The majority of reported pathogenic mutations in the CAPRIN1 gene result in decreased protein levels and haploinsufficiency; however, they can also result in protein expansion. We present the case of a patient with ASD, gross motor delay, fine motor delay, speech delay, mixed receptive-expressive language disorder, incontinence, and ADHD. Whole exome sequencing was significant for a likely pathogenic variant in the maternally inherited CAPRIN1 gene, c. 1045 C > T, p. (Q349*), with clinical correlation supporting a diagnosis of CAPRIN1-related neurodevelopmental disorder. Further analysis demonstrated that the patient's likely pathogenic variant in the CAPRIN1 gene, c. 1045 C > T, p. (Q349*), was a nonsense mutation, de novo and heterozygous, likely resulting in loss of function of the CAPRIN1 protein. This novel mutation in the CAPRIN1 gene has not been previously described in the literature. This novel variant is consistent with the most common identified CAPRIN1 mutations, and his phenotypic presentation included the most common symptoms reported with CAPRIN1 mutations, including language impairment and speech delay, ADHD, ASD, respiratory symptoms, as well as ataxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.